Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akcea Therapeutics Inc. AKCA

Healthcare Biotechnology
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are... see more

Recent & Breaking News (NDAQ:AKCA)

Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program

Canada NewsWire March 13, 2020

Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company's leadership team

GlobeNewswire March 11, 2020

Akcea Supports Rare Disease Day 2020 and Global Efforts to "Reframe Rare"

GlobeNewswire February 28, 2020

Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 26, 2020

Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019

GlobeNewswire February 25, 2020

Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast

GlobeNewswire February 18, 2020

Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman

GlobeNewswire February 13, 2020

Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

GlobeNewswire January 28, 2020

Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

PR Newswire January 22, 2020

Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

GlobeNewswire January 10, 2020

New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

GlobeNewswire January 2, 2020

Akcea Retains Rights to AKCEA-APOCIII-LRx

GlobeNewswire December 18, 2019

Akcea Therapeutics Announces New Appointments to its Board of Directors

GlobeNewswire December 16, 2019

Akcea Announces Appointment of New Chief Operating Officer

GlobeNewswire December 4, 2019

Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

GlobeNewswire November 25, 2019

Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

GlobeNewswire November 19, 2019

Akcea Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2019

Akcea Reports Financial Results and Highlights for Third Quarter 2019

GlobeNewswire November 5, 2019

Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day

GlobeNewswire November 1, 2019

Akcea Announces Appointment of New Chief Commercial Officer

GlobeNewswire October 23, 2019